C
Cyclarity Therapeutics
About Cyclarity Therapeutics
Underdog Pharmaceuticals, now rebranded as Cyclarity Therapeutics, is a biopharmaceutical company that operates in the healthcare sector. The company is primarily focused on developing innovative treatments for age-related diseases, with a particular emphasis on atherosclerosis, a condition characterized by the hardening and narrowing of the arteries.
Cyclarity's unique approach involves targeting toxic forms of cholesterol with specially designed molecules. This method aims to not just manage the symptoms of diseases like atherosclerosis, hypercholesterolemia, heart failure, and macular degeneration, but to modify the disease itself, potentially reversing its effects. This is a significant departure from traditional treatments, which typically focus on managing symptoms rather than addressing the root cause of the disease.
The company's primary clients are patients suffering from these age-related diseases. By offering a potential cure rather than just symptom management, Cyclarity has the potential to disrupt the healthcare market significantly.
Cyclarity's business model is based on the research, development, and commercialization of its disease-modifying treatments. The company makes money by selling these treatments to healthcare providers, who then administer them to patients.
In summary, Cyclarity Therapeutics is a forward-thinking biopharmaceutical company that aims to revolutionize the treatment of age-related diseases by targeting their root causes rather than just managing symptoms.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Sep 2021 | $10M | $40M | Kizoo | — |
| SPINOUT✓Other financing | Nov 2019 | $0 | — | SENS Research Foundation | — |
Growth signals
Latest recorded traffic for Cyclarity Therapeutics is 2.2K monthly website visits, down 45% over the last three months. Cyclarity Therapeutics's team grew 31.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Cyclarity Therapeutics in the Novato ecosystem
The Cyclarity Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Other known investors4 additional known investors
SENS Research Foundation
California Life Sciences
Formic Ventures
Small Business Innovation Research
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cyclarity Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cyclarity Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










